HeartBeam Q4 net loss widens

Heartbeam

12/03/2026 20:36

Overview

U.S. cardiac monitoring tech firm's Q4 and full yr net loss widened vs prior yr

Company received FDA clearance for cable-free 12-lead ECG synthesis software in Dec 2025

HeartBeam began limited commercial launch and signed first commercial partnership with ClearCardio

Outlook

Company plans broader expansion across multiple U.S. geographies following initial rollout

Result Drivers

Research and development expenses for the fourth quarter of 2025 were $3.4 million, compared to $2.9 million for the fourth quarter of 2024

INCREASED R&D SPENDING - Higher research and development expenses driven by new product development, including extended-wear ECG patch and AI-ECG algorithms

Cash and cash equivalents totaled $4.4 million as of December 31, 2025, as compared to $2.4 million at December 31, 2024

Company press release: ID:nBw8Qmjwza

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$21.02 mln
FY Basic EPS
-$0.62
FY Income From Operations
-$21.14 mln
FY Operating Expenses
$21.14 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Heartbeam Inc is $4.75, about 249.3% above its March 11 closing price of $1.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)